Molecular determinants of the response of tumor cells to boswellic acids

Pharmaceuticals

Volumn 4, Issue 8, 2011, Pages 1171-1182

  Eichhorn, Tolga ^a   Greten, Henry Johannes ^b   Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Heidelberg School of Chinese Medicine   (Germany)

Author keywords

Apoptosis; Boswellia; Ceramide; Frankincense; Natural products; Olibanum; Pharmacogenomics; Sphingomyelin

Indexed keywords

ALPHA BOSWELLIC ACID; BETA BOSWELLIC ACID; BORNEOL; BOSWELLIC ACID; DOXORUBICIN; FARNESOL; LIMONENE; MELPHALAN; MESSENGER RNA; PACLITAXEL; TENIPOSIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BOSWELLIA; BOSWELLIA CARTERII; CANCER INHIBITION; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG STRUCTURE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IC 50; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHYTOCHEMISTRY; RNA METABOLISM; TRANSCRIPTOMICS; TUMOR CELL;

EID: 80052193906     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4081171     Document Type: Article

References (25)

1. Martinez, D.; Lohs, K.; Janzen, J. Weihrauch und Myrrhe. Kulturgeschichte und Wirtschaftliche Bedeutung. Botanik, Chemie, Medizin (Germany); Wissenschaftliche Verlagsgesellschaft: Stuttgart, Germany, 1989.
2. Ammon, H.P.T. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006, 72, 1100-1116.
3. Ammon, H.P.T. Modulation of the immune
4. Shao, Y.; Ho, C.T.; Chin, C.K.; Badmaev, V.; Ma, W.; Huang, system by Boswellia serrata extracts and boswellic acids. Phytomedicine 2010, 17, 862-867.M.T. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cells in culture. Planta Med. 1998, 64, 328-331.
5. Glaser, T.; Winter, S.; Groscurth, P.; Safayhi, H.; Sailer, E.R.; Ammon, H.P.; Schabet, M.; Weller, M. Boswellic acids and malignant glioma: Induction of apoptosis but no modulation of drug sensitivity. Br. J. Cancer 1999, 80, 756-765.
6. Hoernlein, R.F.; Orlikowsky, T.; Zehrer, C.; Niethammer, D.; Sailer, E.R.; Simmet, T.; Dannecker, G.E.; Ammon, H.P.T. Acetyl-11-keto-b-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits Topoisomerase I. J. Pharmacol. Exp. Ther. 1999, 288, 613-619.
7. Winking, M.; Sarikaya, S.; Rahmanian, A.; Jodicke, A.; Boker, D.K. Boswellic acids inhibit glioma growth: A new treatment option? J. Neurooncol. 2000, 46, 97-103.
8. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4, 540-550.
9. de Marzo, A.M.; Platz, E.A.; Sutcliffe, S.; Xu, J.; Grönberg, H.; Drake, C.G.; Nakai, Y.; Isaacs, W.B.; Nelson, W.G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007, 7, 256-269.
10. Thorsteinsdottir, S.; Gudjonsson, T.; Nielsen, O.H.; Vainer, B.; Seidelin, J.B. Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 395-404.
11. Alley, M.C.; Scudiero, D.A.; Monks, A.; Hursey, M.L.; Czerwinski, M.J.; Fine, D.L.; Abbott, B.J.; Mayo, J.G.; Shoemaker, R.H.; Boyd, M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988, 48, 589-601.
12. Monk, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
13. Scherf, U.; Ross, D.T.; Waltham, M.; Smith, L.H.; Lee, J.K.; Tanabe, L.; Kohn, K.W.; Reinhold, W.C.; Myers, T.G.; Andrews, D.T., et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000, 24, 236-244.
14. Amundson, S.A.; Do, K.T.; Vinikoor, L.C.; Lee, R.A.; Koch-Paiz, C.A.; Ahn, J.; Reimers, M.; Chen, Y.; Scudiero, D.A., Weinstein, J.N., et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 2008, 68, 415-424.
15. Efferth, T.; Fabry, U.; Osieka, R. Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997, 11, 1180-1186.
16. Wosikowski, K.; Schuurhuis, D.; Johnso, K.; Paull, K.D.; Myers, T.G.; Weinstein, J.N.; Bates, S.E. Identification of epidermal growth factor receptor and erbB2 pathway inhibitors by correlation with gene expression patterns. J. Natl. Cancer Inst. 1997, 89, 1505-1515.
17. Ernst, E. Frankincense: Systematic review. BMJ 2008, 337, a2813.
18. Goldie, J.H.; Coldman, A.J. A model for tumor response to chemotherapy: An integration of the stem cell and somatic mutation hypotheses. Cancer Invest. 1985, 3, 553-564.
19. Luria, S.E.; Delbrück, M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943, 28, 491-511.
20. Dy, G.K.; Adjei, A.A. Systemic cancer therapy: Evolution over the last 60 years. Cancer 2008, 113, 1857-1887.
21. Efferth, T.; Herrmann, F.; Tahrani, A.; Wink, M. Cytotoxic activity towards cancer cells of arteanuine B, artemisitene, scopoletin and 1,8-cineole derived from Artemisia annua L. in comparison to artemisinin. Phytomedicine 2011, In Press.
22. Leteurtre, F.; Kohlhagen, G.; Paull, K.D.; Pommier, Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J. Natl. Cancer Inst. 1994, 86, 1239-1244.
23. Efferth, T.; Gebhart, E.; Ross, D.D.; Sauerbrey, A. Identification of gene expression profiles predicting tumor cell response to l-alanosine. Biochem. Pharmacol. 2003, 66, 613-621.
24. Efferth, T.; Olbrich, A.; Bauer, R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 2002, 64, 617-623.
25. Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targets 2011, 12, 122-132.